William Ragatz

Bill has more than 25 years of experience in the pharmaceutical and biotech industry. Most recently, Bill was Senior Vice President, Head of Commercial at Viela Bio where he built and led the global commercial organization and created the overall commercial vision for bringing pipeline assets to market.  As an officer of the company, he was an integral team member for their IPO and the acquisition by Horizon Therapeutics. Prior to joining Viela, Bill was a Director for AstraZeneca where he led the worldwide commercial strategy for anifrolumab in systemic lupus erythematosus. Bill also spent 15 years at Boehringer-Ingelheim in roles of increasing responsibility, including leading the launch of respiratory, cardiovascular and oncology products. Bill started his pharmaceutical career at Merck and received his MBA from the Fuqua School of Business at Duke University. Bill brings to Sentrimed significant and broad commercial experience along with expertise in building strong organizations and successfully developing pipeline assets.

Dr. Jack Goldberg, MD

Jack Goldberg has over 40 years of experience and expertise in conducting clinical trials in oncology. In addition, he has basic research experience in hematopoietic stem cells and translational research in cancer. He has authored over 70 peer reviewed publications. He has been an active member of the Cancer and Acute Leukemia Group B and the Leukemia Intergroup. He has participated and directed clinical trials focused on leukemia and experience in bone marrow transplantation. He established community wide cancer research and received funding from the NIH for Community Clinical Oncology Program of New Jersey. He has also served from 1986 to 1989 as the Chairperson of the NCI Biology and Immunology Contracts Review Committee. He served the American Cancer Society Professor of Clinical Oncology from 1992 to 2002. In addition to Federal and NIH contributions, he established the Cooper Cancer Institute in Camden New Jersey in 1988, and the Abramson Comprehensive Cancer Center at Penn Presbyterian in 2002. He was certified by the American Board of Internal Medicine in 1976, American Subspecialty Board of Hematology in 1980, and American Subspecialty Board of Oncology in 1990. He serves on the board of the American Cancer Society Camden County. He will offer Sentrimed and our group of collaborators his years of experience in organizing and conducting clinical research in oncology.

Dr. Bradley S. Galer, MD

Dr. Galer has served as Zogenix Executive Vice President and Chief Medical Officer since December 2013, where he was involved in the licensing and global development of fenfluramine (FINTEPLA) for the treatment of rare devastating childhood-onset epilepsies, including Dravet syndrome and Lennox Gastaut syndrome. Prior to joining Zogenix, Dr. Galer served as President at Nuvo Research, a specialty pharmaceutical company with three commercialized topically delivered pain products. From 2000-2005 Dr. Galer was Endo Pharmaceuticals’ Senior Medical Officer and Group Vice President, Scientific Affairs. Prior to joining industry, Dr. Galer was on faculty at University of Washington and Albert Einstein College of Medicine.  He has published over 200 articles in peer review journals and textbooks. Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco. Dr. Galer offers Sentrimed significant scientific, medical, and product development experience.

Mr. Richard Kitei, JD

Richard Kitei earned his Bachelor’s degree from the University of Pennsylvania where he was involved in clinical research. He also has a Master’s degree from Georgetown University where he interned in the Intellectual Property division of the Department of Justice. He received his law degree from Temple University with a merit scholarship while working at 2 law offices and a technology transfer office. He has worked in technology development at the NIAID of the NIH where he worked with parasitic disease and immunogenetics intramural labs. He has also been involved as an employee, investor, and board member in various technology, health, and nanotech startup companies. He has been working with Rowan’s technology commercialization department since early 2018, and in the General Counsel office since early  2019. He has been licensed by PA and NJ and USPTO bars. Rick is well positioned to help Sentrimed achieve our scientific and business goals.

Christoper Leonard

Mr. Leonard has been working as an elementary school science specialist in Boston Public Schools since 2010.  Before that he spent 25 years with the community organization, ACORN, holding several positions, including Head Organizer (director), Massachusetts and D.C. chapters, and Massachusetts Campaign Director.  In his capacity as head organizer, some of his responsibilities included overseeing the organization’s finances and staffing, and working with the board of directors.  While Massachusetts Campaign Director, he ran a successful statewide campaign to enact predatory lending legislation in 2004.  Mr. Leonard is an early investor in the company and has previously served as President.

Mari Rhodehamel Yin

Mari is the treasurer at Sentrimed where she is responsible for overseeing the financial operations of the company including assets from NIH grants and other funding. Upon starting with Sentrimed she immediately implemented strict accounting controls and oversight. Her focus is ongoing risk management and process optimization. Prior to joining Sentrimed, she had over twenty years of management consulting experience in designing and implementing employee compensation structures for the global pharmaceutical and health insurance industries. Mari ensured companies could rapidly update employee compensation due to ever changing marketplace conditions such as a production difficulties, rollout of new products, and merging of companies. This was done while ensuring expeditious and accurate payroll execution with enhanced job satisfaction and company morale. Her experience also encompasses budget, vendor and contract management, forecasting, and organization optimization. Mari earned her Master of Science in Information Systems at Drexel University and her Bachelor of Arts in Political Science at Hiram College.